Heptares Therapeutics and Kymab Limited have entered a partnership to jointly undertake an antibody discovery and development programme using the former’s StaR platform and the latter’s Kymouse.
According to the agreement, Heptares Therapeutics will generate stable antigens to target Gprotein-coupled receptors (GPCR) and Kymab will create antibodies as a result of immunisation with the antigens.
The partnership enables both companies to yield highly potent antigens and human monoclonal antibodies and allows them to develop an immuno-oncology-based treatment for cancer.
AC Immune has entered an agreement to partner with Biogen to develop new disease modifying therapies for Parkinson’s disease and synucleinopathies associated with the disease. The partners will also develop novel therapeutics for neurodegenerative disease such as amyotrophic lateral sclerosis.
Under the three-year partnership agreement, Biogen is responsible for the funding, while AC Immune will handle the intellectual and property rights.
AC Immune will further undertake chemistry and biology research of alpha-synuclein PET tracer for Parkinson’s disease and the TDP-43 PET programme. TDP 43 is a protein target in the pathogenesis of diseases such as Lou Gehrig’s Disease.
Biogen will carry out the scientific assessment and radiopharmaceutical development of AC Immune compounds.
R-Biopharma and HMNC Brain Health have entered a co-development agreement for the further development and optimisation of the potency of depression therapy.
As part of the agreement, R-Biopharma will develop in-vitro polymerase chain reaction (PCR)-based genetic test.
In addition, the two companies will develop, gain regulatory approvals, manufacturing and commercialisation of ABCB1 genetic test to trace the ABCB1 variants in patients taking anti-depressants.
BioMotiv plans to raise funds through private placement of its common stock to support its drug development process.
The placement will be subscribed to by Arix Biosciences Limited, which will have an option to co-invest and nominate a member to BioMotiv advisory board.
Gross proceeds from the transaction will amount to $25m.
Recipharm has announced it will issue common stock in rights offering to raise $104.46m. It has further announced that Kemfin Holdings and an undisclosed minority owner will be issued a part of the offering prior to the record date.
The company plans to invest proceeds from the offering to acquire Kemwell Biopharma’s pharmaceutical contract development and manufacturing (CDMO) businesses.
Kemwell Biopharma is a provider of biopharmaceutical contract services.
Image: AC immune will undertake the chemistry and biology research of alpha-synuclein PET tracer. Photo: courtesy AC Immune.